Form 8-K - Current report:
SEC Accession No. 0001641172-25-003913
Filing Date
2025-04-14
Accepted
2025-04-11 19:04:26
Documents
17
Period of Report
2025-04-11
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 40374
2 ex3-1.htm EX-3.1 9625
3 ex3-2.htm EX-3.2 9061
4 ex3-3.htm EX-3.3 5114
  Complete submission text file 0001641172-25-003913.txt   250171

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE aneb-20250411.xsd EX-101.SCH 3011
6 XBRL LABEL FILE aneb-20250411_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE aneb-20250411_pre.xml EX-101.PRE 22356
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 4068
Mailing Address C/O ANEBULO PHARMACEUTICALS, INC. 1017 RANCH ROAD 620 SOUTH, SUITE 107 LAKEWAY TX 78734
Business Address C/O ANEBULO PHARMACEUTICALS, INC. 1017 RANCH ROAD 620 SOUTH, SUITE 107 LAKEWAY TX 78734 737 203 5270
Anebulo Pharmaceuticals, Inc. (Filer) CIK: 0001815974 (see all company filings)

EIN.: 851170950 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-40388 | Film No.: 25833875
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)